Ind-Swift Laboratories Ltd

BSE :532305 NSE :INDSWFTLAB Sector : Pharmac..
83.83
Change: 1.12(1.35%)
52 week Low
80.41
52 week High
186.00
Day low
82.75
Day high
84.98
Prev Close
82.71
Open
84.90
6M return
-27.51%
1Y return
-36.20%
MCap(Rs. in Cr.)
508.17
Total Volume
1,33,155
Face Value : 10
Listed Since
PE Ratio

Is the price-earnings ratio for valuing a company that measures its current share price relative to its earnings per share.

P/E RATIO
6.12161
EPS

The earnings per share ratio is a portion of company's net profit allocated for each outstanding share. It is calculated by deducting preferred stock divided from the net income of the company divided by the number of outstanding shares.

EPS
13.65
PRICE/BOOK

Price-to-book ratio is used to compared the company's current market price with its book value.

PRICE/BOOK
0.49
Deliverable

These are the acutal number of shares that are traded on delivery based, meaning transfered from one person to another during the day's trade.

DELIVERABLES
69.94%
DIV YIELD.(%)

Dividend Yield measures the quantum of cash dividends paid to shareholders in a financial year relative to the market value of the per share.

DIV YIELD.(%)
0.00

Company Details

Check out the key parameters of the company to understand the financial health and stock performance

Key Level

Resistance 1
83.67
Resistance 2
84.64
Support 1
81.87
Support 2
81.04

Moving Average

20 Days
88.13
50 Days
93.40
100 Days
99.78
200 Days
116.98
Growth in 3 years

Sales
23.31%

Sales Industry Avg
16.38%

PAT
-19,702.33%

PAT Industry Avg
37.18%

Dec 2024
( in Cr.)
Sep 2024
( in Cr.)
Jun 2024
( in Cr.)
Mar 2024
( in Cr.)
FY 2024
( in Cr.)
Sales8.6611.9633.17393.331,280.90
Gross Profit-0.840.801.23499.83635.06
Operating Profit00000
Profit Before Tax-1.090.580.98498581.76
Tax-1.080.18-0.03145.31160.31
Profit After Tax-0.010.401.01352.69421.45
Growth in 3 years

Total Asset Growth
-39.58%

Total Liabilities growth
-39.57%

Reserves Change
61.20%

Mar 2024
( in Cr.)
Mar 2023
( in Cr.)
Mar 2022
( in Cr.)
Mar 2021
( in Cr.)
Mar 2019
( in Cr.)
Share Capital59.0959.8159.8159.8148.08
Reserves And Surplus872.37622.13541.16543.70555.86
Investments110.5430.3429.0635.5318.56
Total Debt17.86879.98970.171,021.221,129.80
Total Liabilities949.301,561.921,571.031,624.641,733.74
Total Assets949.281,561.921,571.021,624.641,733.73
No data available


Relative to Sensex rtn in 3 year
-45.69%

Relative to Nifty rtn in 3 year
-48.85%



1 Year (%)2 Year (%)3 Year (%)
Ind-swift Labs.-363315
Bse Sensex12627
Nifty 5013029

Peer Companies

A quick glance on how stocks from the same sector have performed along with some key parameters

Ind-Swift Labs.
83.83
Change: 1.12 (1.35%)
1 Year return
-36.20%
Risk (Std Dev)
0.19%
PE Ratio
6.12161
MCap( in Cr.)
508.17
Emcure Pharma
919.45
Change: 919.45 (0.00%)
1 Year return
0.00%
Risk (Std Dev)
-
PE Ratio
28.64671
MCap( in Cr.)
17,422.05
Sai Life
669.50
Change: 29.25 (4.57%)
1 Year return
-12.44%
Risk (Std Dev)
0.12%
PE Ratio
101.12538
MCap( in Cr.)
13,953.34
Blue Jet Health
683.55
Change: 57.50 (9.18%)
1 Year return
74.91%
Risk (Std Dev)
0.11%
PE Ratio
50.76
MCap( in Cr.)
11,857.23
Sanofi Consumer
4,943.20
Change: 57.00 (1.17%)
1 Year return
0.81%
Risk (Std Dev)
0.04%
PE Ratio
56.57
MCap( in Cr.)
11,384.50
View More

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

 

If I had made
investment of  
in
Months Ago
My investment would be worth 63,797.60 with a Loss of -36.20%

Our Research Reports

Stocks and sector-wise Research Reports by HDFC securities help you analyse, understand and take a informed investment decision.

Periodic Reports 16 Sep 2014 10:25 AM
Buy Ind-Swift Laboratories between Rs 36.60 and Rs 35. Stoploss at Rs 33

News

Stay tuned to the latest developments and happenings in the company.

Ind-Swift Laboratories adjourns board meeting

Ind-Swift Laboratories has adjourned the meeting of the Board of Directors which was scheduled to be held on 12 February 2025. The meeting will now b....

14 Feb 2025 11:01

Ind-Swift Laboratories announces cessation of director

Ind-Swift Laboratories announced the cessation of Dr. Ashwani Kumar Vig as Independent Director of the Company on completion of his tenure with effec....

13 Feb 2025 19:26

Ind-Swift Laboratories adjourns board meeting

Ind-Swift Laboratories has adjourned the meeting of the Board of Directors which was scheduled to be held on 12 February 2025. The meeting will now b....

13 Feb 2025 11:33

Ind-Swift Laboratories consolidated net profit declines 98.70% in the September 2024 quarter

Net profit of Ind-Swift Laboratories declined 98.70% to Rs 0.41 crore in the quarter ended September 2024 as against Rs 31.66 crore during the previou....

12 Nov 2024 07:42

Ind-Swift Laboratories consolidated net profit declines 94.55% in the June 2024 quarter

Net profit of Ind-Swift Laboratories declined 94.55% to Rs 0.94 crore in the quarter ended June 2024 as against Rs 17.24 crore during the previous qua....

13 Aug 2024 07:32

Ind-Swift Laboratories standalone net profit declines 63.70% in the June 2024 quarter

Net profit of Ind-Swift Laboratories declined 63.70% to Rs 6.19 crore in the quarter ended June 2024 as against Rs 17.05 crore during the previous qua....

13 Aug 2024 07:31

View More
Subscribe for our
newsletter
Open Account Now